$22.420
-1.484 (-6.62%)Al cierre
Noticias de SRZN
Eventos de SRZN
Surrozen Q1 Revenue Hits $5M, Exceeds Consensus
Reports Q1 revenue $5M, consensus $4M. The company said, "Surrozen remains focused on advancing a new generation of ophthalmology therapeutics that are built on a foundation of Wnt pathway biology. Surrozen's pipeline leverages its Wnt biology expertise and antibody technologies to develop therapeutics targeting ophthalmic diseases with significant unmet medical needs."
Surrozen Files $200M Mixed Securities Shelf
Surrozen files $200M mixed securities shelf
Surrozen appoints Andrew Maleki as Chief Financial Officer
Andrew Maleki has joined the Surrozen management team as CFO. Maleki brings more than a decade of experience in the biotech industry spanning corporate strategy, business development and operational leadership, including playing a key role in raising over $500M in capital. Most recently, he led corporate development and program leadership at Lassen Therapeutics, where he helped shape portfolio strategy and business development efforts.
Surrozen granted patent from USPTO directed to antibody-based molecules
Surrozen announced the issuance of U.S. Patent No. 12,297,278. Surrozen has six issued U.S. patents, 10 patents issued in other countries, 11 patent families pending in the U.S. and other countries, five patent families pending in the U.S. only, two pending PCT applications, and four patent families with pending U.S. provisional applications, and has two in-licensed patent families related to the Wnt pathway and its modulation. In May 2025, Surrozen was granted U.S. Patent No. 12,297,278 related to its SWAPTM technology. The patent covers tetravalent, multi-specific Wnt surrogates comprised of: two Frizzled binding regions that specifically bind to two Fzd receptors, wherein each of the two Fzd binding regions comprises an antibody or antigen-binding fragment of the antibody; and two LRP5/6 binding regions that specifically bind to a Low-density lipoprotein receptor-related protein 5 and/or a LDL receptor-related protein 6, wherein each of the two LRP5/6 binding regions comprises an antibody or antigen-binding fragment of the antibody, and wherein each of the two LRP5/6 binding regions is fused to one of the two Fzd binding regions via a linker moiety.
Surrozen files to sell 5.21M shares of common stock for holders
The company is not selling any of its common stock pursuant to this prospectus, and will not receive any proceeds from the sale of its common stock offered by this prospectus by the selling stockholders.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.